Evidence map›Paper›PMID 39621278›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

Testing Oncolytic Myxoma Virus in Immunocompetent Mouse Model for Cancer Therapy.

Yasmin Shakiba, Masmudur M Rahman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yasmin ShakibaSchool of Medical and Biological Physics, Moscow Institute of Physics and Technology, Moscow, Russia.
Masmudur M RahmanCenter for Personalized Diagnostics, Biodesign Institute, Arizona State University, Tempe, AZ, USA. masmudur.rahman@asu.edu.

Funding

Studies in Poxvirus Host Range Genes and TropismR01AI080607 · NIAID · UNIVERSITY OF FLORIDA · PI RAHMAN, MASMUDUR MOHAMMED · 2009 to 2025
$5.6M
Cancer therapy with a combination of oncolytic bacteria and virus to enhance targeted cell killing and anti-tumor immune responsesR21CA249517 · NCI · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI KONG, WEI, RAHMAN, MASMUDUR MOHAMMED · 2021 to 2022
$400k
NCI NIH HHS R21 CA249517NIAID NIH HHS R01 AI080607
6 · The paper itself

Abstract

Oncolytic viruses (OVs) have emerged as a class of novel cancer immunotherapeutic. Members of both DNA and RNA viruses developed as OVs for treating diverse types of human cancers. Preclinical research assessing immunotherapeutic efficacy is an essential step toward further development of these OVs. Mice tumor model systems are widely used in preclinical oncolytic viral therapies for evaluating the treatment regimens' efficacy. However, choosing the most appropriate model for a study can be challenging. Here, we describe a simple method of establishing subcutaneous tumors in immunocompetent mice, intratumoral injection of the virus, measuring tumor burden, and studying the survival of mice for preclinical development of oncolytic myxoma virus (MYXV).

Indexed as

Disease Models, AnimalMyxoma virusOncolytic VirotherapyOncolytic VirusesAnimalsCell Line, TumorFemaleHumansImmunocompetenceMiceNeoplasmsTumor BurdenB16F10Cancer cellsMyxoma virusOncolytic virotherapyOncolytic virusPreclinical mouse model

Identifiers

PMID39621278
PMCPMC11724751

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.